Washington:  The Trump administration is preparing a fresh investigation into global drug pricing, a move that could lead to new tariffs on imported pharmaceuticals. The inquiry aims to examine whether U.S. trading partners pay significantly less for prescription drugs compared to American consumers, who often face prices nearly three times higher than those in other developed countries.

The probe is expected to proceed under Section 301 of the Trade Act of 1974, which allows the U.S. to take action against unfair trade practices. While the White House has not officially commented, the initiative aligns with President Trump’s previous threats to impose a 100% tariff on branded or patented drug imports unless companies set up manufacturing plants in the United States.

Earlier this year, Trump sent letters to 17 major pharmaceutical companies urging them to lower U.S. drug prices to match those in other nations. The administration’s renewed focus on drug pricing underscores its push for “America First” policies in healthcare.

If tariffs are eventually imposed, the move could have wide-ranging effects on the global pharmaceutical industry and international trade relations. The White House has yet to respond to media requests for comment on the report.